[go: up one dir, main page]

WO2025250667A1 - Dérivés d'amide de n-(1-(tert-butyl)-1h-pyrazol-4-yl)-2-(4-((6-(quinolin-4-yl)oxy)-phényl)acet utilisés en tant qu'inhibiteurs de ripk2 pour le traitement de maladies inflammatoires - Google Patents

Dérivés d'amide de n-(1-(tert-butyl)-1h-pyrazol-4-yl)-2-(4-((6-(quinolin-4-yl)oxy)-phényl)acet utilisés en tant qu'inhibiteurs de ripk2 pour le traitement de maladies inflammatoires

Info

Publication number
WO2025250667A1
WO2025250667A1 PCT/US2025/031234 US2025031234W WO2025250667A1 WO 2025250667 A1 WO2025250667 A1 WO 2025250667A1 US 2025031234 W US2025031234 W US 2025031234W WO 2025250667 A1 WO2025250667 A1 WO 2025250667A1
Authority
WO
WIPO (PCT)
Prior art keywords
otq
alkyl
compound
disease
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/031234
Other languages
English (en)
Inventor
Chad VANHUIS
Dominik K. KOELMEL
William R. Roush
Shifeng Pan
Robert AVERSA
Sebastian Schneider
Natalie A. Dales
Arun P. THOTTUMKARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Odyssey Therapeutics Inc
Original Assignee
Odyssey Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odyssey Therapeutics Inc filed Critical Odyssey Therapeutics Inc
Publication of WO2025250667A1 publication Critical patent/WO2025250667A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des inhibiteurs de RIPK2 de formules (I) ou (II) pour le traitement, par exemple, de maladies inflammatoires, de maladies auto-immunes, de maladies granulomateuses, de maladies neurodégénératives ou du cancer, et plus particulièrement pour le traitement de la polyarthrite rhumatoïde, de l'arthrite inflammatoire, de la péritonite, d'une lésion d'ischémie-reperfusion dans la transplantation rénale, de la stéatohépatite non alcoolique, de la stéatohépatite alcoolique, du diabète de type 2 résistant à l'insuline, de la rhinite allergique, de l'asthme, de la dermatite atopique, du syndrome de Sjögren, de la spondylarthrite, de la spondylarthrite ankylosante, du pemphigus vulgaris, de la lymphadénopathie plasmacytique idiopathique, de l'athérosclérose, de l'infarctus du myocarde, de la thrombose, de l'alpha-synucléinopathie, de la maladie de Parkinson, de la démence à corps de Lewy, de l'atrophie multisystémique, de la maladie d'Alzheimer, de la sclérose latérale amyotrophique et de la bronchopneumopathie chronique obstructive.
PCT/US2025/031234 2024-05-29 2025-05-28 Dérivés d'amide de n-(1-(tert-butyl)-1h-pyrazol-4-yl)-2-(4-((6-(quinolin-4-yl)oxy)-phényl)acet utilisés en tant qu'inhibiteurs de ripk2 pour le traitement de maladies inflammatoires Pending WO2025250667A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463653119P 2024-05-29 2024-05-29
US63/653,119 2024-05-29
US202463722813P 2024-11-20 2024-11-20
US63/722,813 2024-11-20

Publications (1)

Publication Number Publication Date
WO2025250667A1 true WO2025250667A1 (fr) 2025-12-04

Family

ID=96220399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/031234 Pending WO2025250667A1 (fr) 2024-05-29 2025-05-28 Dérivés d'amide de n-(1-(tert-butyl)-1h-pyrazol-4-yl)-2-(4-((6-(quinolin-4-yl)oxy)-phényl)acet utilisés en tant qu'inhibiteurs de ripk2 pour le traitement de maladies inflammatoires

Country Status (1)

Country Link
WO (1) WO2025250667A1 (fr)

Similar Documents

Publication Publication Date Title
EP4291559A1 (fr) Composés de pyrrolo[3,2-d]pyrimidine et méthodes d'utilisation dans le traitement du cancer
US11248007B2 (en) Inhibitors of MALT1 and uses thereof
JP6878004B2 (ja) リンパ形質細胞性リンパ腫を処置する方法
JP2018530554A (ja) ブロモドメイン阻害薬及びチェックポイント阻害薬による併用療法
AU2014292888A1 (en) Inhibitors of transcription factors and uses thereof
JP2016505001A (ja) Ｐｒｍｔ５阻害剤およびその使用
JP2020529998A (ja) 血漿カリクレインの阻害剤およびその使用
WO2021222542A1 (fr) Dérivés de 5-amino-2-pipéridinon-3-yl-1-oxoisoindoline pour la dégradation des agents de dégradation ikzf2
EP4377306A1 (fr) Inhibiteurs de rock2 et leurs utilisations
EP3577103A1 (fr) Composés anti-fibrotiques
AU2023386005A1 (en) Inhibitors of ripk2 and medical uses thereof
WO2025250667A1 (fr) Dérivés d'amide de n-(1-(tert-butyl)-1h-pyrazol-4-yl)-2-(4-((6-(quinolin-4-yl)oxy)-phényl)acet utilisés en tant qu'inhibiteurs de ripk2 pour le traitement de maladies inflammatoires
JP2024517789A (ja) グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用
JP2025539828A (ja) Ｒｉｐｋ２の阻害剤及びその医学的使用
WO2024259328A1 (fr) Inhibiteurs de ripk2 et leurs utilisations
JP2025513813A (ja) ヒストン脱アセチル化酵素６（ｈｄａｃ６）の阻害
WO2025193888A1 (fr) Antagonistes de pyridazinone c5ar1 et leurs utilisations
WO2017151625A1 (fr) Dérivés de 4,9-dioxo 4,9-dihydronaphto(2,3-b) furan-3-carboxamide et leurs utilisations pour le traitement de maladies prolifératives et de maladies infectieuses